Patricia Lo Russo, DO
Medical Oncology · Detroit, MINPI 1932146420
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $242,885 of the $321,612 with a category attached, or 75.5%. It is spread thinly across 30 manufacturers, the largest accounting for just 20.5%. 2025 is the largest year on record at $127,509, 3.8 times the $33,966 reported in 2019. Among medical oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $1495.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim Pharma GmbH & Co.kg$66K
- Boehringer Ingelheim International GmbH$46K
- Pfizer$38K
- Amgen$21K
- F. Hoffmann-la Roche AG$20K
- Merck Healthcare Kgaa$17K
- plus $113K from 24 others
Across 3,474 payments — averaging $7012.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$3.4M
- Genentech, Inc.$2.8M
- AstraZeneca$2.2M
- Pfizer$2.1M
- Boehringer Ingelheim$1.7M
- Astellas Pharma Inc$1.6M
- plus $10.5M from 36 others
What the payments were for
- Consulting fees$242,88576%
- Speaking & faculty fees$27,0288%
- Travel & lodging$47,74915%
- Food & beverage$3,9501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim Pharma GmbH & Co.kg | 16 | $65,988 |
| Boehringer Ingelheim International GmbH | 56 | $46,109 |
| Pfizer(2 entities) | 21 | $38,471 |
| Amgen | 18 | $21,300 |
| F. Hoffmann-la Roche AG | 9 | $19,518 |
| Merck Healthcare Kgaa | 5 | $17,221 |
| EMD Serono, Inc. | 10 | $15,914 |
| AstraZeneca | 8 | $12,221 |
| Merck | 13 | $11,557 |
| EMD Serono Research & Development Institute, Inc. | 2 | $11,121 |
| Genentech USA, Inc. | 16 | $10,278 |
| Ipsen Biopharmaceuticals, Inc | 4 | $9,240 |
| GSK | 4 | $6,519 |
| Kyowa Kirin, Inc. | 4 | $5,642 |
| Stemline Therapeutics Inc. | 2 | $5,440 |
| SK Life Science, Inc. | 2 | $5,338 |
| Foundation Medicine, Inc. | 1 | $4,758 |
| Astrazeneca UK Limited | 3 | $4,678 |
| Seagen Inc. | 2 | $2,680 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,845 |
| Bristol Myers Squibb | 1 | $1,321 |
| Janssen Research & Development, LLC | 1 | $1,320 |
| Eli Lilly | 3 | $1,098 |
| Jazz Pharmaceuticals Inc. | 1 | $1,000 |
| Boehringer Ingelheim | 4 | $624 |
| Genentech, Inc. | 2 | $156 |
| Gilead | 1 | $97 |
| Tesaro, Inc. | 2 | $76 |
| Lilly USA, LLC | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELZONRIS$5,440
- LUMAKRAS$5,087
- TECENTRIQ$4,873
- Herceptin$4,806
- Perjeta$4,806
- SOMATULINE DEPOT$3,850
- Cenobamate$3,238
- XCOPRI$2,100
- TUKYSA$1,650
- Non-Covered Product$1,619
- ZEPZELCA$1,000
- IMFINZI$343
How this compares
$321,612 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Detroit
- Philip PhilipDetroit$494K
- Shirish GadgeelDetroit$413K
- Ammar SukariDetroit$273K
- Charles SchifferDetroit$165K
- Ahmed KasebDetroit$107K
- Bassel El-RayesDetroit$76K
- Haythem AliDetroit$34K
- Dipesh UpretyDetroit$21K
- Clara HwangDetroit$16K
- Amy WeiseDetroit$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.